Project Grant R01CA300696
- Federal Project Grant Award Summary Cedars-Sinai Medical Center received a $662,610 Project Grant from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded April 1, 2026, with a completion date of March 31, 2031. The award funds research to develop universal methylated circulating tumor DNA (ctDNA) markers for minimal residual disease (MRD) detection and therapy response prediction in colorectal cancer (CRC). The research...
- Federal Grant Award Summary Cedars-Sinai Medical Center received an $858,798 Project Grant (R21) from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) awarded on August 18, 2025, with a completion date of July 31, 2027. The award supports a two-investigator research project investigating the role of extracellular vesicles (EVs) enclosed with circular RNA (circRNA) in modulating immune responses within the prostate cancer tumor microenvironment. The research...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Icahn School of Medicine at Mount Sinai a $697,131 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective May 1, 2026, through April 30, 2031. This research initiative addresses immune resistance mechanisms in colorectal cancer (CRC), specifically targeting the myeloid-stromal axis that suppresses anti-tumor immunity in microsatellite stable cases resistant to immune checkpoint blockade. The research...
- Federal Grant Award Summary The National Cancer Institute awarded a $710,361 Project Grant under the Cancer Biology Research program (CFDA 93.396) to J. David Gladstone Institutes, effective August 1, 2025, through May 31, 2030. This award funds the development of a spatial profiling-based immune hub perturbation platform designed to improve immunotherapy efficacy in colorectal cancer (CRC). The research addresses a critical gap in preclinical modeling by creating experimental frameworks that...
- Federal Grant Award Summary The National Cancer Institute awarded a $730,398 Project Grant to Sloan-Kettering Institute for Cancer Research under the Cancer Treatment Research program (CFDA 93.395) beginning April 1, 2026, and extending through March 31, 2031. This award supports research investigating tumor regenerative cell (TRC) populations that drive resistance to neoadjuvant therapy and metastatic recurrence in locally advanced rectal cancer (LARC). The research deliverables include genomic...
- Federal Project Grant Award Summary Cedars-Sinai Medical Center received a $191,700 Project Grant award from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) effective September 1, 2025, through August 31, 2028. This award supports research investigating the etiology and tumor characteristics of early-onset pancreatic cancer. The project delivers two primary research services: (1) investigation of associations between early-onset pancreatic cancer...
- Federal Grant Award Summary Cedars-Sinai Medical Center received a $617,748 Project Grant from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273), awarded September 10, 2025, with performance completion targeted for June 30, 2030. The research project, titled "The Role of Prohibitin 1 in Ethanol's Sensitizing Effect on Colorectal Liver Metastasis," will investigate the molecular mechanisms by which alcohol consumption...
- Federal Grant Award Summary Cedars-Sinai Medical Center received a $167,000 Project Grant award, effective September 1, 2025 through August 31, 2027, from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310). The award supports research focused on vascular niche restoration to prevent delayed effects of acute radiation exposure (DEARE) in the hematopoietic system. The research addresses the long-term health risks faced by...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Feinstein Institutes for Medical Research a $167,500 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through July 31, 2027. This research initiative addresses chronic lymphocytic leukemia (CLL), the most prevalent adult leukemia in the United States, by investigating the cellular and molecular mechanisms underlying communication between cancer cells and...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $421,685 Project Grant to The Regents of the University of California, San Francisco under the Cancer Biology Research program (CFDA 93.396) for research activities spanning August 8, 2025 through July 31, 2027. This award funds a discovery-focused research initiative investigating functional immune niches within the tumor microenvironment (TME) that support effective cancer immunotherapy responses. The primary deliverable...
Cedars-Sinai Medical Center received a $708,990 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective May 1, 2026 through April 30, 2031. The grant supports fundamental research investigating the microenvironmental and hepatocyte cell type-specific regulation of colorectal cancer (CRC) metastasis by the IL17 cytokine. The research aims to elucidate how IL17 signaling in hepatocytes and myeloid cells (particularly neutrophils) creates "metastasis-permissive" niches that suppress anti-tumor immune responses in the liver microenvironment. The project will employ genetic models of IL17 receptor complex (IL17RC) deficiency, IL17 cytokine neutralization strategies, advanced preclinical CRC metastasis models, histological and imaging techniques, and transcriptomics analysis to understand how microbially-induced IL17 regulates the tumor microenvironment during metastasis development and how IL17 inactivation drives anti-tumor immunity through innate and adaptive immune mechanisms. The research addresses a significant clinical challenge, as metastatic CRC shows poor responsiveness to immunotherapies and other treatment modalities, and elevated IL17A expression correlates with poor prognosis and liver metastasis in CRC patients. The deliverables will include scientific findings, data, and publications advancing understanding of cancer immunology mechanisms relevant to metastatic disease prevention and treatment innovation.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $709.0k | 4/7/26 |